Ideas intended to address Minnesota’s opioid crisis, immediately and into the future, received strong House support Monday night.
Sponsored by Rep. Liz Olson (DFL-Duluth), HF400, as amended, features a wide range of measures to address an issue that led many members — on both sides of the aisle — to speak during the four-hour discussion about their personal experiences with the opioid epidemic and their support for a broad, multi-faceted approach.
Passed 94-34, the bill now goes to the Senate, where there is no direct companion.
“We are in the midst of an opioid addiction crisis,” Olson said. “Parents have lost children. Teachers have lost students … no other family deserves to go through this.”
[WATCH — Full video of floor debate on the bill]
A crisis decades in the making will also require “years of dedicated, ongoing revenue” to be adequately addressed, and that revenue should be provided by the industry responsible, not taxpayers, Olson said.
But disagreements remain regarding bill’s proposed funding mechanism: registration fees, to be paid by pharmaceutical manufacturers and distributors and collected by the Board of Pharmacy.
Manufacturers’ fees would be required to total $12 million per year, while wholesalers’ fees would be required to equal $8 million. Each organization’s share of these amounts would be pro-rated and determined by its percentage of the overall sale and distribution of opioids in the state.
These funds would go into a designated account, which would also collect any money received through settlement or court orders related to opioid litigation.
This money would be allocated to address the opioid epidemic through programs focused on prevention and education as well as intervention, treatment, and recovery.
While enthusiastic about the initiatives supported by the bill, opponents expressed their belief that this funding structure would increase health care costs for people who legitimately need opioids for the management of severe pain and life-threatening conditions.
Other concerns expressed included the possible risk of litigation, which could jeopardize funding.
Several Republicans mentioned their willingness to support the bill if it was funded differently and expressed hope that a different source could be identified and agreed on during conference committee.
“This funding mechanism acts as a disincentive to drug manufacturers and distributors because their costs will skyrocket,” as the number of prescriptions issued fall in the state, said Rep. Nick Zerwas (R-Elk River).
Rep. Zack Stephenson (DFL-Coon Rapids) countered the state is already paying from the General Fund to address the opioid crisis, through the operation of jails and prisons, out-of-home child placements, and health costs.
“It’s about responsibility,” Rep. Laurie Halverson (DFL-Eagan) said. “We are asking for these companies that helped manufacture this crisis in our state, and around the country, and around the world, to be part of the solution.”
Floor amendments that were adopted would:
Amendments voted down include a few attempts to amend the bill with a sunset provision.